News

Bonti is focused on developing fast-acting neurotoxin programs intended to be used in aesthetic and therapeutic applications. According to the acquisition terms, the Irish drug maker will make

Alopecia areata is an autoimmune disease evidenced by hair loss and often linked with profound psychological consequences. The PF-06651600 is an oral JAK 3 inhibitor, while PF-06700841 is a

AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for

Lumoxiti, which is a CD22-directed cytotoxin, has been approved for the patients who had two or prior systemic therapies, including treatment with a purine nucleoside analog. AstraZeneca executive

Actemra can be given alone or in combination with methotrexate (MTX) in patients with SJIA. In 2011, FDA approved the intravenous (IV) formulation of Actemra for patients two

ViraTherapeutics is engaged in the development of virus-based immunotherapeutics for the treatment of cancer. The current deal is based on an option and share purchase agreement signed by

Praliciguat is an investigational, orally administered soluble guanylate cyclase (sGC) stimulator currently in Phase II clinical trials. Ironwood chief development officer and global development senior vice president Christopher

VEYVONDI should not be used in the treatment of hemophilia A. VEYVONDI is the first and only recombinant von Willebrand Factor (rVWF) treatment in the EU for von Willebrand disease (VWD)

To encourage Regeneron’s expansion in New York State, Empire State Development offered the company up to $140 million in performance-based incentives, including $70 million in Excelsior Jobs Program